GlassScriptPhysician profile
Hal J Jenkins
NPI 1487674016
$13,136.49
in general payments reported to CMS, 2019-2025
56 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $1,247 · 2021: $1,427 · 2022: $2,007 · 2023: $1,871 · 2024: $2,292 · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,713 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.85 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,800.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,350.24 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,273.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,223.52 | 2019-2025 | |
| Lilly USA, LLC | $1,197.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $811.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $668.32 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.03 | 2019-2024 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $348.57 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $333.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $326.16 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $261.52 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $251.12 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.02 | 2020-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $210.65 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.